Teva commences launch of Bupropion 150 mg

Bupropion is the generic equivalent of GlaxoSmithKline's Wellbutrin.

Teva Pharmaceutical Industries Ltd. (Nasdaq: TEVA) announced yesterday that, pursuant to its July 2003 agreement with Andrx Corporation and Impax Laboratories, Inc., it has begun commercially shipping Bupropion Hydrochloride 150 mg controlled release tablets.

Bupropion Hydrochloride Tablets are the AB-rated generic equivalent of GlaxoSmithKline's Wellbutrin SR. This product is indicated for the treatment of depression.

Annual sales of the brand product are approximately $1.3 billion.

Published by Globes [online] - www.globes.co.il - on Tuesday, March 23, 2004

Twitter Facebook Linkedin RSS Newsletters גלובס Israel Business Conference 2018